GlycoMAb works by genetically engineering the antibody-producing cells with a gene encoding an oligosaccharide-modifying enzyme.more
The mission of the Roche Innovation Center Zurich is to be a leader in developing new generations of engineered antibody products with increased efficacy that address unmet clinical needs. The Center is also an antibody engineering power-house within the Roche Group.
Glycart Biotechnology was established in September 2000 as a spin-off of the Swiss Federal Institute of Technology (ETH) in Zurich, Switzerland. In the summer of 2005, the young biotech company was acquired by the Roche Group.
The state-of-the-art research complex headquartered in Schlieren, Switzerland, is now an integral part of Roche Pharmaceutical Research and Early Development. The Roche Innovation Center Zurich boasts a multinational team of some 140 employees – 95% of whom are research scientists – with a dynamic, thriving biotech culture. The Roche Innovation Center Zurich is headed by Pablo Umaña, Ph.D., and comprises research teams in diverse fields as diverse as molecular biology, cell and protein engineering, process biochemistry, cell biological assays, histology, preclinical pharmacology and tumor immunology. The teams belong to global functions such as Large Molecule Research, Oncology Discovery and Translational Area, and Infectious Diseases Discovery.
The Roche Innovation Center Zurich focuses on product development – from scientific concepts and validation to the corresponding studies. Today the compounds studied and developed are boosting Roche’s significant commitment to offering improved cancer medicines.
Benefits of GlycoMAb
Roche Glycart AG Wagistrasse 18 CH-8952 Schlieren Schweiz
+41 44 755 6161
Roche Glycart AG
Tel.: +41 44 755 6161
Fax: +41 44 755 6160
For more information please visit the following websites: